Individualized estimates of overdiagnosis in screen-detected prostate cancer

Journal of the National Cancer Institute

Volumn 106, Issue 2, 2014, Pages

  Gulati, Roman ^a   Inoue, Lurdes Y T ^b   Gore, John L ^c   Katcher, Jeffrey ^a   Etzioni, Ruth ^a  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGE; AGED; ARTICLE; BLOOD; CANCER GRADING; CANCER STAGING; COMPUTER SIMULATION; EARLY DIAGNOSIS; FEMALE; HUMAN; IMMUNOLOGY; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; NOMOGRAM; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROSTATE TUMOR; RISK; STATISTICAL MODEL; UNITED STATES; VERY ELDERLY; WATCHFUL WAITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; COMPUTER SIMULATION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; WATCHFUL WAITING;

EID: 84893845633     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt367     Document Type: Article

References (19)

1. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U. S. Preventive Services Task Force. Ann Intern Med. 2011;155(11):762-771.
2. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-383.
3. Gulati R, Wever EM, Tsodikov A, et al. What if i don't treat my PSAdetected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev. 2011;20(5):740-750.
4. Kattan MW. Do we need more nomograms for predicting outcomes in patients with prostate cancer? Nat Clin Pract Urol. 2008;5(7):366-367.
5. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003;170(5):1792-1797.
6. Partin AW, Kattan MW, Subong EN, et al. Combination of prostatespecific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277(18):1445-1451.
7. Gulati R, Inoue L, Katcher J, et al. Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics. 2010;11(4):707-719.
8. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013;158(3):145-153.
9. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19(2):175-181.
10. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. New Engl J Med. 2003;349(3):215-224.
11. Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol. 2005;174(3):877-881.
12. Mariotto A, Etzioni R, Krapcho M, et al. Reconstructing prostate-specific antigen (PSA) testing patterns among black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer. 2007;109(9):1877-1886.
13. Pinsky PF, Andriole GL, Kramer BS, et al. Prostate biopsy following a positive screen in the Prostate, Lung, Colorectal and Ovarian cancer screening trial. J Urol. 2005;173(3):746-750; discussion 750-751.
14. Babaian RJ, Toi A, Kamoi K, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol. 2000;163(1):152-157.
15. Presti J C J, Chang JJ, Bhargava V, et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol. 2000;163(1):163-166; discussion 166-167.
16. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
17. Harrell FJ. RMS: regression modeling strategies. R package version 3.6-3. 2013. http://cran. r-project.org/package=rms. Accessed July 1, 2013.
18. Cho H, Mariotto A, Mann BS, et al. Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. Am J Epidemiol. 2013;178 (3) 339-349.
19. Wilt T, Brawer MK, Jones K, et al. Radical prostatectomy versus observation for localized prostate cancer. New Engl J Med. 2012;367(3):203-213.